Daiichi-Sankyo Slashing 1,000+ US Jobs Ahead Of Benicar Expiry
This article was originally published in Scrip
Japanese major Daiichi-Sankyo is preparing to cut up to 1,200 mainly sales positions in the US ahead of the loss of exclusivity for blockbuster antihypertensive Benicar, and amid a shift in its business model away from primary care and toward specialty products.
You may also be interested in...
Highlighting progress it has made over the past few years, Japan’s regulatory agency says it wants to raise even further the number of “Japan-first” approvals, as part of its stated mission to get safe and effective new drugs to patients more quickly.
Join us for a brief audio tour around the past week's key developments in the global biopharma industry, in this podcast version of Scrip's Five Must-Know Things.
Given its ever-growing role as a critical component of the global biopharma industry, you can’t afford not to be up to speed on Asia. This biweekly selection of insights from our experienced on-the-ground team will help.